Sarit Assouline
Overview
Explore the profile of Sarit Assouline including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
106
Citations
4055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Busque L, Beaudet M, Harnois M, Moussa H, Szuber N, Mollica L, et al.
Blood Cancer J
. 2025 Mar;
15(1):35.
PMID: 40069191
No abstract available.
2.
Brailovski E, Harnois M, Busque L, Chamakhi I, Tremblay A, Desjardins P, et al.
Br J Haematol
. 2025 Feb;
206(3):981-983.
PMID: 39948763
No abstract available.
3.
Bhella S, Wilkin A, Hueniken K, Vijenthira A, Sebag M, Wang P, et al.
Vaccine
. 2024 Jun;
42(24):126074.
PMID: 38944577
Background: Immune response to COVID-19 vaccine is diminished in patients with hematologic malignancy. There is limited data regarding response to vaccine doses in these patients. Purpose: To quantify the humoral...
4.
Budde L, Assouline S, Sehn L, Schuster S, Yoon S, Yoon D, et al.
J Clin Oncol
. 2024 Mar;
42(19):2250-2256.
PMID: 38547425
JCO Mosunetuzumab is a CD20xCD3 T-cell-engaging bispecific antibody administered as an off-the-shelf, fixed-duration treatment in an outpatient setting. We report an updated analysis of the durability of response, by investigator...
5.
Konopleva M, Dail M, Daver N, Garcia J, Jonas B, Yee K, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Feb;
24(6):364-374.
PMID: 38378362
Background: Therapies for relapsed/refractory acute myeloid leukemia remain limited and outcomes poor, especially amongst patients who are ineligible for cytotoxic chemotherapy or targeted therapies. Patients And Methods: This phase 1b...
6.
7.
STAT6 mutations enriched at diffuse large B-cell lymphoma relapse reshape the tumor microenvironment
Benoit A, Abraham M, Li S, Kim J, Estrada-Tejedor R, Bakadlag R, et al.
Int J Hematol
. 2024 Jan;
119(3):275-290.
PMID: 38285120
Diffuse large B-cell lymphoma (DLBCL) relapses in approximately 40% of patients following frontline therapy. We reported that STAT6 mutations are enriched in relapsed/refractory DLBCL (rrDLBCL) samples, suggesting that JAK/STAT signaling...
8.
Matasar M, Bartlett N, Shadman M, Budde L, Flinn I, Gregory G, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jan;
24(4):240-253.
PMID: 38195322
Background: Mosunetuzumab is a CD20xCD3 T-cell engaging bispecific antibody approved in Europe and the United States for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. Materials And Methods:...
9.
Budde L, Olszewski A, Assouline S, Lossos I, Diefenbach C, Kamdar M, et al.
Nat Med
. 2023 Dec;
30(1):229-239.
PMID: 38072960
Relapsed/refractory aggressive large B cell lymphoma (LBCL) remains an area of unmet need. Here we report the primary analysis of a phase 1b/2 trial of outpatient mosunetuzumab (a CD20xCD3 T-cell-engaging...
10.
Osborne M, Sulekha A, Culjkovic-Kraljacic B, Gasiorek J, Ruediger E, Jolicouer E, et al.
J Mol Biol
. 2023 Dec;
436(2):168378.
PMID: 38043731
The UDP glucuronosyltransferases (UGT) deactivate many therapeutics via glucuronidation while being required for clearance of normal metabolites and xenobiotics. There are 19 UGT enzymes categorized into UGT1A and UGT2B families...